idarubicin


Also found in: Wikipedia.

idarubicin

 [i″dah-roo´bĭ-sin]
an antitumor antibiotic of the anthracycline group, administered intravenously in the treatment of acute myelogenous leukemia.

idarubicin

/ida·ru·bi·cin/ (i″dah-roo´bĭ-sin) an anthracycline antineoplastic used as the hydrochloride salt in the treatment of acute myelogenous leukemia.

idarubicin

an antibiotic and antineoplastic.
indications This drug is used in combination with other antineoplastics for acute myelocytic leukemia in adults.
contraindications Pregnancy, hypersensitivity, lactation, and myelosuppression prohibit the use of this drug.
adverse effects Adverse effects of this drug include hypertension, extrasystoles, ventricular tachycardia, bundle branch block, atrioventricular block, palpitations, supraventricular extrasystoles, syncope, and nausea. Common side effects include headache, hypotension, and bradycardia. Life-threatening side effects include sinus arrest, congestive heart failure, and arrhythmias.

idarubicin

4-demethoxydaunorubicin Oncology An antitumor antibiotic

idarubicin

A CYTOTOXIC anti-cancer drug. A brand name is Zavedos.

idarubicin

an anthracycline antibiotic used as an antineoplastic agent; similar to doxorubicin.
References in periodicals archive ?
Contract notice: Supply of salmeterol, Salmeterol / fluticasone and idarubicin association for all osakidetza service organizations
5 FOLFOX 0 IAP 0 ABVD: Adriamycin, bleomycin, vinblastine, dacarbazine, ICE: Ifosfamide, carboplatin, etoposide, ECF: Epirubicin, cisplatin, 5-fluorouracil, FEC: 5-fluorouracil, epirubicin, cyclophosphamide, IA: Idarubicin, Cytarabine, CHOP: Cyclophosphamide, hydroxyl-daunorubicin, oncovin, prednisone, FOLFOX: Fluorouracil, leucovorin, oxaliplatin, IAP: Oxaliplatin, epirubicin, ifosfamide Table 3: Adverse effects in study subjects Adverse n (%) effects Interventional group Non-interventional group Nausea 0 1 (5) Diarrhea 3 (15) 4 (20) Dizziness 2 (10) 1 (5) Vomiting 3 (15) 5 (25) Headache 2 (10) 2 (10) Dysgeusia 4 (20) 2 (10)
Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: Results from study AML-BFM 2004.
The patient subsequently underwent induction chemotherapy (Cytarabine and Idarubicin (7 + 3)).
2] of intravenous idarubicin (IDA) was added to ATRA on days 2, 4, 6, and 8.
Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS.
The patient underwent a 7+3 chemotherapy regimen with Ara-C and Idarubicin.
Additionally, anti-leukemic drugs used clinically include daunorubicin, Idarubicin, vincristine, paclitaxel, cisplatin, doxorubicin, arsenic trioxide and etoposide that have potent pro-oxidant activity (Martin-Cordero et al.
This acute myeloid leukemia that occurred on the background of a myelodysplastic syndrome was treated with cytarabine 250 mg/day 7 days+ idarubicin 15 mg/day 3 days.